Biblio
KK-LC-1 as a therapeutic target to eliminate ALDH stem cells in triple negative breast cancer. Nat Commun. 2023;14(1):2602.
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway. Sci China Life Sci. 2023.
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study. Elife. 2023;12.
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23(1):88.
. Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer. Mol Cancer. 2024;23(1):3.
. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer. 2023;22(1):6.
.